Skip to main content
. 2024 Mar 23;18:917–927. doi: 10.2147/OPTH.S452159

Table 3.

IOP and IOP-Lowering Medication Outcomes at Baseline and Each Post-Implant Time Point in the Total Population and Subgroups Differentiated by Baseline IOP of 21 mmHg

Parameter Baseline Month 1 Month 6 Month 12
Eyes with decrease in IOP ≥20%, n (%)
 Total population NA 44 (28.21) 47 (30.13) 64 (41.03)
 IOP≥21 NA 28 (52.83) 30 (56.60) 39 (73.58)
 IOP<21 NA 16 (15.53) 17 (16.50) 25 (24.27)
Medication-free, n (%)
 Total population 33 (21.15) 114 (73.08) 97 (62.18) 67 (42.95)
 IOP≥21 21 (39.62) 36 (67.92) 30 (56.60) 22 (41.51)
 IOP<21 12 (11.65) 78 (75.73) 67 (65.05) 45 (43.69)
Reduction in medications ≥1, n (%)
 Total population NA 100 (64.10) 92 (58.97) 81 (51.92)
 IOP≥21 NA 20 (37.74) 17 (32.08) 16 (30.19)
 IOP<21 NA 80 (77.67) 75 (72.82) 65 (63.11)
Same or lower number of medications
 Total population NA 153 (98.1%) 144 (92.3%) 127 (81.4%)
 IOP≥21 NA 51 (96.2%) 46 (86.8%) 36 (67.9%)
 IOP<21 NA 102 (99%) 88 (85.4%) 91 (88.3%)

Abbreviations: IOP, intraocular pressure; NA, not applicable.